Trial Schema

<table>
<thead>
<tr>
<th>Biopsy</th>
<th>Assessment of extent of tumour by imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Patient registration and completion of pre-operative TESS questionnaire</em></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wide local excision of sarcoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wound healing and assessment</td>
</tr>
</tbody>
</table>

| Oncology appointment post-operation |

**Randomisation**
Stratified by: tumour grade, adequacy of definitive surgical clearance and centre

Radiotherapy planning

### Control Arm
Conventional two-phase treatment
Total dose: 66Gy in 33#

- **Weeks 1-5**
  - 2Gy x 5 days Weekly
  - CTV₁
    - 5cm margin to GTV or 1cm to the scar, whichever is longer in the cranio-caudal direction and minimum margin of 2cm axially

- **Week 6**
  - 2Gy x 5 days

- **Week 7**
  - 2Gy x 3 days

### Research Arm
Single-phase treatment to CTV₂ only
Total dose: 66Gy in 33#

- **Weeks 1-6**
  - 2Gy x 5 days Weekly

- **Week 6**
  - 2Gy x 5 days

- **Week 7**
  - 2Gy x 3 days

- CTV₂
  - 2 cm cranio-caudal margin to GTV and minimum margin of 2cm axially

---

*Patient Registration and TESS completion after written informed consent obtained.*

** Patient to be randomised in order for protocol treatment (radiotherapy) to begin within 12 weeks of surgery.

CTV: Clinical Target Volume